3 documents

Read All
21:52 , May 5, 2017 |  BioCentury  |  Finance

Magenta’s match

Be the Match BioTherapies’ first ever equity investment was motivated by desire to back a company that shared its goal of helping transplant patients achieve better outcomes, rather than by a planned strategic shift toward...
Read More
20:00 , May 5, 2017 |  BC Week In Review  |  Company News

Novartis grants Magenta rights to MGTA-456

Novartis AG (NYSE:NVS; SIX:NOVN) granted Magenta Therapeutics Inc. (Cambridge, Mass.) rights to MGTA-456 (formerly HSC835) in selected applications, including immune and blood diseases. The product comprises umbilical cord blood hematopoietic stem cells that have been expanded...
Read More
18:14 , May 2, 2017 |  BC Extra  |  Financial News

Magenta raises $50M, strikes pair of deals

Stem cell transplant company Magenta Therapeutics Inc. (Cambridge, Mass.) raised $50 million in an oversubscribed series B round led by GV. The company also announced separate partnerships with Novartis AG (NYSE:NVS; SIX;NOVN) and Be The...
Read More